Methods of treating a fatty acid amide hydrolase-mediated condition

Patent metadata

Field	Value
Publication number	US-9951089-B2
Application number	US-201514631712-A
Country	US
Kind code	B2
Filing date	Feb 25, 2015
Priority date	Feb 3, 2010
Publication date	Apr 24, 2018
Grant date	Apr 24, 2018

Abstract

The present invention provides fatty acid amide hydrolase inhibitors, solid forms thereof, compositions thereof, and methods of making and using the same.

First claim

We claim:

1. A method of treating an FAAH-mediated condition comprising administering to a subject in need thereof a therapeutically effective amount of a solid form of a crystalline compound of formula 1:

or a pharmaceutically acceptable salt, hydrate, or solvate thereof, or anhydride thereof, wherein the crystalline compound of formula 1 is a Form A crystal form of formula 1 having an X-ray powder diffraction pattern comprising peaks at approximate peak positions of 17.26±0.10, 21.60±0.10, and 27.73±0.10 degrees 2θ and at least one peak at an approximate peak position of 9.68±0.10, 24.68±0.10, 25.48±0.10, and 29.08±0.10 degrees 2θ, wherein the FAAH-mediated condition is a painful condition.

2. The method according to claim 1 , wherein the FAAH-mediated condition is a painful condition selected from the group consisting of inflammatory pain, joint pain, arthritic pain, lumbosacral pain, musculoskeletal pain, headache, migraine, muscle ache, lower back pain, neck pain, and toothache dental/maxillofacial pain.

3. The method according to claim 1 , wherein the FAAH-mediated condition comprises diabetic neuropathy, sciatica, non-specific lower back pain, multiple sclerosis pain, fibromyalgia, HIV-related neuropathy, neuralgia, post-herpetic neuralgia, trigeminal neuralgia, or pain resulting from chronic inflammatory conditions.

4. The method according to claim 1 , wherein the FAAH-mediated condition comprises post-herpetic neuralgia.

5. The method according to claim 1 , wherein the FAAH-mediated condition comprises arthritic pain associated with crystalline arthritis, osteoarthritis, psoriatic arthritis, gouty arthritis, reactive arthritis, rheumatoid arthritis, or Reiter's arthritis.

6. The method according to claim 1 , wherein the FAAH-mediated condition comprises joint pain.

7. The method according to claim 1 , wherein the FAAH-mediated condition comprises arthritic pain.

Assignees

• Infinity Pharmaceuticals Inc

Inventors

• Austad Brian C
• Grenier Louis
• Grogan Michael J
• Liu Tao
• White Priscilla L
• Martinot Theodore A
• Yu Lin-Chen

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P9/12

  Antihypertensives · CPC title

• A61P37/02

  Immunomodulators · CPC title